Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Authors:
Open Access
- 18 December 2018
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 4 (1) , 41
Abstract
CDK4 & 6 inhibitors have enhanced the effectiveness of endocrine therapy (ET) in patients with advanced breast cancer (ABC). This paper presents exploratory analyses examining patient and disease characteristics that may inform in whom and when abemaciclib should be initiated. MONARCH 2 and 3 enrolled women with HR+, HER2- ABC. In MONARCH 2, patients whose disease had progressed while receiving ET were administered fulvestrant+abemaciclib/placebo. In MONARCH 3, patients received a nonsteroidal aromatase inhibitor+abemaciclib/placebo as initial therapy for advanced disease. A combined analysis of the two studies was performed to determine significant prognostic factors. Efficacy results (PFS and ORR in patients with measurable disease) were examined for patient subgroups corresponding to each significant prognostic factor. Analysis of clinical factors confirmed the following to have prognostic value: bone-only disease, liver metastases, tumor grade, progesterone receptor status, performance status, treatment-free interval (TFI) from the end of adjuvant ET, and time from diagnosis to recurrence. Prognosis was poorer in patients with liver metastases, progesterone receptor-negative tumors, high grade tumors, or short TFI (20 months. These analyses identified prognostic factors and demonstrated that patients with poor prognostic factors derived the largest benefit from the addition of abemaciclib.Keywords
This publication has 26 references indexed in Scilit:
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Treating cancer with selective CDK4/6 inhibitorsNature Reviews Clinical Oncology, 2016
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directionsWorld Journal of Clinical Oncology, 2014
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival AnalysisAdvances in Therapy, 2013
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- A small sample study of the STEPP approach to assessing treatment–covariate interactions in survival dataStatistics in Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognostic factors for patients with hepatic metastases from breast cancerBritish Journal of Cancer, 2003